FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1351-1352 November 1, 2001 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The early deaths reported by Sargent et al. (July 12 issue)¹ among patients with colorectal cancer who were enrolled in trials N9741 and C89803 have aroused concern regarding the use of irinotecan in combination with fluorouracil and leucovorin. In these trials, a weekly bolus regimen of fluorouracil and leucovorin was combined with irinotecan. A different regimen of infusional fluorouracil and leucovorin, with or without irinotecan,² is being used in three large, ongoing European trials. The Pan-European Trials in Adjuvant Colon Cancer 3 randomly assigned 1668 patients with stage III colon cancer to receive infusional fluorouracil and leucovorin . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Aranda, E., Valladares, M., Martinez-Villacampa, M., Benavides, M., Gomez, A., Massutti, B., Marcuello, E., Constenla, M., Camara, J. C., Carrato, A., Duenas, R., Reboredo, M., Navarro, M., Diaz-Rubio, E. (2008). Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Ann Oncol 0: mdn557v1-mdn557 [Abstract] [Full Text]  
• Folprecht, G., Seymour, M. T., Saltz, L., Douillard, J.-Y., Hecker, H., Stephens, R. J., Maughan, T. S., Van Cutsem, E., Rougier, P., Mitry, E., Schubert, U., Kohne, C.-H. (2008). Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. JCO 26: 1443-1451 [Abstract] [Full Text]  
• Toffoli, G., Cecchin, E., Corona, G., Russo, A., Buonadonna, A., D'Andrea, M., Pasetto, L. M., Pessa, S., Errante, D., De Pangher, V., Giusto, M., Medici, M., Gaion, F., Sandri, P., Galligioni, E., Bonura, S., Boccalon, M., Biason, P., Frustaci, S. (2006). The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer. JCO 24: 3061-3068 [Abstract] [Full Text]  
• Kohne, C.-H., van Cutsem, E., Wils, J., Bokemeyer, C., El-Serafi, M., Lutz, M.P., Lorenz, M., Reichardt, P., Ruckle-Lanz, H., Frickhofen, N., Fuchs, R., Mergenthaler, H.-G., Langenbuch, T., Vanhoefer, U., Rougier, P., Voigtmann, R., Muller, L., Genicot, B., Anak, O., Nordlinger, B. (2005). Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. JCO 23: 4856-4865 [Abstract] [Full Text]  
• Yao, M., Zhou, W., Sangha, S., Albert, A., Chang, A. J., Liu, T. C., Wolfe, M. M. (2005). Effects of Nonselective Cyclooxygenase Inhibition with Low-Dose Ibuprofen on Tumor Growth, Angiogenesis, Metastasis, and Survival in a Mouse Model of Colorectal Cancer. Clin. Cancer Res. 11: 1618-1628 [Abstract] [Full Text]  
• Kohne, C-H., Wils, J., Lorenz, M., Schoffski, P., Voigtmann, R., Bokemeyer, C., Lutz, M., Kleeberg, U., Ridwelski, K., Souchon, R., El-Serafi, M., Weiss, U., Burkhard, O., Ruckle, H., Lichinitser, M., Langenbuch, T., Scheithauer, W., Baron, B., Couvreur, M.L., Schmoll, H.J. (2003). Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. JCO 21: 3721-3728 [Abstract] [Full Text]